Concepedia

Amitkumar Mehta

AM

Statistics

Publications

57

Citations

5.1K

H-Index

30

Active since

2013

Affiliations

University of Alabama at Birmingham(Current)

The University of Texas MD Anderson Cancer Center

City Of Hope National Medical Center

University of Michigan

Memorial Sloan Kettering Cancer Center

Amitkumar Mehta is an author at University of Alabama at Birmingham specializing in oncology, medicine, and immunotherapy.

Publications per year

2013–2025

57

Publications

57

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning et al. · The Lancet · 2020 · 2.3K citations

Medicine, Oncology, Pharmacology +13

PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Bradley M. Haverkos, Diana Abbott, Mehdi Hamadani et al. · Blood · 2017 · 242 citations · Full text

Medicine, Hematology, Oncology +17

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson et al. · Journal of the National Comprehensive Cancer Network · 2019 · 189 citations · Full text

Medicine, Hematology, Oncology +15

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Nancy L. Bartlett, Alex F. Herrera, Eva Domingo‐Doménech et al. · Blood · 2020 · 151 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett et al. · The Lancet Oncology · 2019 · 139 citations · Full text

Medicine, Immunology, Oncology +9

1–5 of 57